China Monoclonal Antibody Market by Targets (PD-1, CD20, HER2, VEGF, EGFR, TNF-?Posted by Deeksha on May 16th, 2019 It has been observed that, the global market for China Monoclonal Antibody Market would be experiencing steady growth marked in million US$ by 2025. Such advancements can be attributed to the efforts put in by prime manufacturers operating in the global China Monoclonal Antibody Market during the period 2018-2025. All such statistics and figures are carefully enclosed in a recently uploaded research report titled “China Monoclonal Antibody Market by Targets (PD-1, CD20, HER2, VEGF, EGFR, TNF-?) Research Report”, 2018-2025, onto its broad online database. Readers are enlightened about different aspects associated to the global China Monoclonal Antibody Market which covers growth rate, revenue share, geographical market share, sales channel and Porter’s Five Forces analysis Request Sample Copy of the Report @ https://www.marketresearchhub.com/enquiry.php?type=S&repid=2339972 China’s oncology drug market has grown rapidly in recent years. Revenue of the oncology drugs in China grew from RMB83.4 billion in 2013 to RMB139.4 billion in 2017, representing a CAGR of 13.7%. It is expected to further grow to RMB262.1 billion in 2022 at a CAGR of 13.5% from 2017, and to RMB654.1 billion in 2030 at a CAGR of 12.1% from 2022. While the majority of the top ten oncology drugs globally in 2017 are either molecularly targeted drugs or immuno-oncology drugs, seven out of the top ten oncology drugs in China are chemotherapy drugs and only three are molecularly targeted drugs. This difference between the global market and the China market suggests significant potential for molecularly targeted drug and immuno-oncology drug market growth in China. Three drugs among the top10 oncology drugs globally were recently approved in China in 2018, indicating China is at its early stage of its paradigm shift to molecularly targeted drugs and immuno-oncology drugs. Among all types of cancers, lung cancer, liver cancer, stomach cancer, colorectal cancer and breast cancer are the top five cancer types in China by incidence rate, accounting for more than 50% of the annual incidence in the aggregate. The incidences of lung cancer, colorectal cancer and esophageal cancer are expected to grow at higher CAGRs than the others. Such higher CAGR for lung cancer is attributed to the growing smoking population and air pollution. As for colorectal and esophageal cancer, the higher CAGRs are attributable mainly to increasingly prevalence of unhealthy dietary habits. mAbs (including fusion proteins) only accounted for 5.4% of China’s biologics market in 2017, while globally the figure was 43.2% in the same year, representing a sizable market potential. With the inclusion of more mAbs into the NRDL, sales revenue of China’s mAbs market is expected to grow to RMB69.6 billion in 2022, representing a CAGR of 42.6% from 2017 to 2022, which will outpace the growth of China’s overall biologics market. The diagram below illustrates the size of China’s mAb market from 2013 to 2017 and the estimated market size from 2018 to 2022. In addition to monotherapies, PD-1/L1 inhibitors have shown significant potential in combined therapies. PD-1/PD-L1 inhibitors market is still at an early stage of development but has strong growth potentials. The market size of PD-1 and PD-L1 inhibitors together is estimated to grow to RMB37.4 billion in 2022, representing a CAGR of 534.4% from 2018 to 2022, and further increase to RMB98.4 billion in 2030, representing a CAGR of 12.8% from 2022 to 2030. In December 2018, the State Drug Administration ( NMPA ) announced that it would conditionally approve the listing of the first domestically produced PD-1 monoclonal antibody, tripril monoclonal antibody injection. Tripril monoclonal antibody was developed by Suzhou Zhonghe Biomedical Co., Ltd. (A subsidiary of Shanghai Junshi Biosciences Co., Ltd.) to treat local progression or metastatic melanoma after previous standard treatment failure. Currently, there are 6 PD-1/PD-L1 listed in the world, of which 2 PD-1 drugs, namely Opdivo of Bristol - Myers Squibb and Keytruda of Mercadon, have been approved for listing in China in 2018. Among the domestic R&D companies for PD-1, Innovent Biologics, Inc., Hengrui Medicine and BeiGene, Ltd. have also submitted drug listing applications, but the application indications are all classic Hodgkin lymphoma, and there is no direct competitive relationship with the currently approved indications of Opdivo and Keytruda. Browse Full Report with TOC@ https://www.marketresearchhub.com/report/china-monoclonal-antibody-market-by-targets-pd1cd20her2vegfegfrtnf-research-report-20182025-report.html Table of Content Policy Snapshot 1.1 Snapshot of Policies Overview of Chinese Monoclonal Antibody Market 2.1 China’s Oncology Drug Market Chinese Monoclonal Antibody Market by Target Species 3.1 PD-1/PD-L1 Continued………@#
Like it? Share it!More by this author |